Skip to main content

Table 1 Summary of clinical and pathology data for study participants with a cancer diagnosis

From: Spectral discrimination of breast pathologies in situusing spatial frequency domain imaging

Patient number

Age (years)

Tumor size (cm)

Tumor type

Tumor grade

ER (IHC score)

PR (IHC score)

HER2neu ratio (FISH)

Specimen size (cm)

1

51-55

0.3

DCIS

Low

Pos

Pos

N/A

12.8 × 9.5 × 1.7

2

56-60

7.0

IDCa

High

Neg

Neg

1.1

10.5 × 8.5 × 3.0

3

51-55

2.2

IDCa

Low

Pos

Pos

1.2

7.0 × 6.0 × 1.7

4

61-65

2.2

IDCa

Int

Pos

Pos

1.3

7.0 × 6.8 × 1.3

5

56-60

1.8

IDCa

Int

Pos

Pos

1.0

6.0 × 5.6 × 2.0

6

56-60

2.8

IDCa

High

Neg

Pos

1.1

7.0 × 5.0 × 1.6

7

56-60

1.8

IDCa

Int

Pos

Pos

1.1

9.0 × 7.5 × 2.2

8

56-60

10.0

IDCa**

High

Neg

Neg

6.0

23 × 15 × 6.0

9

56-60

2.0

IDCa**

Int

Neg

Neg

1.0

15 × 15 × 4.0

10

66-70

1.6

IDCa

High

Pos

Neg

1.2

8.5 × 7.0 × 2.0

11

76-80

5.0

DCIS

High

Pos

Pos

N/A

30 × 20 × 5.0

12

56-60

1.6

IDCa

Int

Pos

Pos

1.1

24 × 13 × 3.0

13

56-60

0.8

IDCa**

Int

Pos

Neg

9.0

13.5 × 9.0 × 2.0

14

56-60

6.5

IDCa**

High

Pos

Pos

1.0

22 × 15 × 4.5

15

61-65

5.0

ILCa**

Int

Pos

Pos

1.1

22 × 20 × 5.0

16

71-75

2.5

IDCa

High

Pos

Pos

1.1

7.3 × 7.0 × 3.0

17

61-65

0.4 1.5

IDCa DCIS

Int

Pos

Pos

1.0

9.0 × 8.5 × 2.3

18

56-60

0.5

IDCa

Int

Pos

Pos

1.1

5.0 × 5.0 × 1.3

19

61-65

1.6

IDCa

High

Pos

Pos

1.2

22.5 × 19 × 3.5

20

51-55

2.1

IDCa

Low

Pos

Pos

1.0

7.0 × 5.6 × 1.7

21

61-65

2.4

IDCa

Int

Pos

Pos

1.2

6.7 × 5.6 × 2.0

22

36-40

3.0

IDCa

Int

Pos

Pos

1.2

23 × 23 × 4.0

23

41-45

12.0

IDCa

Int

Pos

Pos

1.1

21 × 18 × 5.0

24

71-75

1.5

IDCa

High

Pos

Pos

1.2

6.0 × 5.0 × 1.6

25

51-55

2.5

IDCa

High

Pos

Pos

1.0

7.0 × 6.5 × 1.4

26

61-65

3.5

IDCa

High

Pos

Neg

1.1

7.5 × 5.0 × 2.7

27

46-50

8.0

IDCa

Int

Pos

Pos

1.2

30 × 29 × 6.0

  1. Tumor size before Rx, maximum dimension for tumor size from pretreatment MRI scan; tumor type: IDCa, infiltrating ductal carcinoma; IDCa**, after chemoRx; ILCa, infiltrating lobular carcinoma. Tumor grade: low, low grade; int, intermediate grade; high, high grade. ER, estrogen-receptor protein; PR, progesterone-receptor protein; IHC score, immunohistochemical semiquantitative score: Pos, (positive) ≥15% IHC staining; Neg (negative), 0 IHC staining. HER2neu ratio, HER2neu gene analysis by fluorescence in situ hybridization (FISH) compared with a normal control, ratio < 2.0 is normal expression, ratio 2 to 4 is equivocal expression, and ratio >4.0 is gene overexpression.